|Day Low/High||22.98 / 22.98|
|52 Wk Low/High||18.94 / 24.20|
Regulatory setbacks helped push Medicines Co. and other biotech stocks down.
A contrarian strategy gives you exposure to the renewed interest in health care-related stocks.
Consider these themes when looking to help boost a portfolio's resistance to recession.
CollaGenex jumps 11% after the FDA approves its pill to treat rosacea.
Its efficient genome-sequencing technology will put the company on the map.
The stock is up 68% over the past year, and more gains could be in store as the company's technology grows.
The sector epitomizes high risk/high reward, but adding some biotech to your portfolio is wise.
Firms are setting more money aside for a rainy day. See which ones top the list.
Companies are setting more money aside for a rainy day. See which ones top the list.
You don't need a lot of money to turn a profit that would make Warren Buffett proud.
The conglomerate teams up with Celera Genomics and Applied Biosystems to fight cancer.
Here's some clarification on volume confirmation. Plus, FirstEnergy, Kraft and more.
Some of the projected savings from big deals such as Pfizer-Pharmacia may come from equipment orders.
The news has analysts rethinking rosy assumptions about the short-term health of this group.
Analysts are concerned with a lack of visibility, but most see a bright spot in the firm's dominant position.
Celera and Applied Biosystems met or beat estimates, but the future looks fuzzy.
Molecular Devices become the second equipment maker to report lower-than-expected earnings.
Sky-high valuation and a revenue warning make it the NYSE's worst quarterly performer.
The chip sector may have moved higher today, but the bears are still out there.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.